Invenra, a Madison, WI-based startup that develops therapeutic antibodies for pharmaceuticals companies and other clients, has raised more than $2.9 million from investors, according to a regulatory filing.

Twenty-five investors participated in the equity funding round, according to the filing, which was made public on Thursday. Invenra, founded in 2011, has now raised more than $14 million in equity and debt financing, according to SEC documents.

Some of the money raised in the latest funding round will go toward research and development efforts, and to compensate executives at the company, Invenra said in the filing.

Invenra’s core business involves discovering antibodies and performing related biology work around targets the startup’s partners have identified in advance. Invenra’s collaborators, which include U.K.-based Oxford BioTherapeutics and Portland, OR-based AgonOx, are then responsible for taking the drugs forward into the clinic. See the full story here.